BI 905711 + FOLFIRI + bevacizumab

BI 905711 + FOLFIRI + bevacizumab is a combination therapy regimen under investigation for advanced gastrointestinal cancers, particularly colorectal cancer and pancreatic ductal adenocarcinoma. **BI 905711** is a novel tetravalent bispecific antibody targeting both TRAILR2 (a death receptor involved in apoptosis) and CDH17 (cadherin-17), designed to selectively induce apoptosis in tumor cells while sparing normal tissue. **FOLFIRI** consists of three drugs: folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan, functioning as a chemotherapeutic backbone; **bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), disrupting tumor angiogenesis. The combination aims to synergistically induce tumor cell death and inhibit tumor growth by targeting cancer cells through multiple mechanisms. Clinical trials are ongoing in patients with advanced colorectal cancer or CDH17-positive pancreatic ductal adenocarcinoma, particularly for those who have progressed on first-line therapy[1][2][3][5].